The future of clinical trials will be shaped by many factors, from innovative enabling technologies to a stronger focus on patient-centricity. The COVID-19 pandemic is testing the resilience of clinical trials in new ways, making it much more difficult to access patients directly. 

In this uncertain environment, decentralising trials may help clinical trials become more resilient. The deployment of remote clinical monitoring is already proving its value in helping to keep trials going at a time when site management is particularly challenging. But realising this transformation requires a flexible mindset, investment in new technologies and close collaboration between stakeholders.  

This FT Digital Dialogue on Innovative Clinical Research Strategies, organised in partnership with ICON plc, discussed how to design and run trials in an uncertain world where the need to decentralise is driving investment in new technology solutions and changing the pharma R&D landscape. 

FT Live events keep you connected and informed in an uncertain and constantly changing world. All access, digital passes include access to all the live sessions PLUS all sessions on demand for 30 days.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice